Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

Conditions: SARS-CoV-2 Infection; COVID-19 Interventions: Biological: BNT162b2; Other: Placebo; Biological: Seasonal Inactivated Influenza Vaccine Sponsors: Pfizer Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials